Full-Time

Senior Director

Regulatory Affairs

Posted on 11/30/2025

Altasciences

Altasciences

1,001-5,000 employees

Integrated CRO for early-phase drug development

Compensation Overview

$150k - $200k/yr

Montreal, QC, Canada + 4 more

More locations: Seattle, WA, USA | Los Angeles, CA, USA | Philadelphia, PA, USA | Overland Park, KS, USA

Hybrid

Category
Legal & Compliance (1)
Required Skills
Google Cloud Platform
Requirements
  • PhD in related discipline preferred.
  • 10 years’ experience in regulatory affairs in a CRO, biotechnology or pharmaceutical setting.
  • Demonstrated success in leading early-stage regulatory strategy and submissions in North America (FDA and Health Canada) for a variety of indications and molecules.
  • Deep knowledge of Health Canada and FDA regulatory frameworks, including CTA and IND processes.
  • Excellent scientific and business judgment.
  • Proven track record practicing sound judgment as it relates to risk assessment.
  • Understanding of Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), and Good Clinical Practice (GCP).
  • Understanding of where to seek and how to interpret regulatory information.
  • Excellent verbal and written communication skills.
  • Professional attitude and strong interpersonal skills.
  • Ability to work well with a multi-disciplinary team.
  • The requirement to have study protocols, designs and clinical research documents written and documented in English as required by industry regulatory agencies.
  • The employee frequently communicates with English-only customers outside the province of Quebec.
  • Reasonable accommodations for persons with disabilities during the recruitment process are available upon request.
Responsibilities
  • Partner with business development to identify and hold initial conversations with potential clients (focusing on clients at the end of the discovery phase).
  • Consult with client pre-award to determine regulatory requirements to meet program needs.
  • Define and prepare regulatory strategy plans.
  • Create, present, and defend content for proposals.
  • Build, mentor, and manage a high-performing regulatory team.
  • Serve as a point of contact for regulatory questions and oversee interactions with regulatory agencies, ensuring effective communication and constructive working relationships with regulatory authority representatives.
  • Partner with Clinical, CDMO, Nonclinical, Medical Writing, and Project Management teams to ensure integrated regulatory planning and execution.
  • Lead the preparation for regulatory meetings (pre-Investigational New Drug Application [IND], pre-Clinical Trial Application [CTA]).
  • Oversee regulatory submission requirements and provide content for regulatory submissions.
  • Implement SOPs and best practices to enhance efficiency and compliance.
  • Monitor the development of new regulatory requirements or guidance documents and advise on the impact on the business or development programs.
  • Identify overall risks to regulatory plans in conjunction with project teams and participate in mitigation strategy team.
Desired Qualifications
  • PhD in related discipline preferred. 10 years’ experience in regulatory affairs in a CRO, biotechnology or pharmaceutical setting.
  • Demonstrated success in leading early-stage regulatory strategy and submissions in North America (FDA and Health Canada) for a variety of indications and molecules.
  • Deep knowledge of Health Canada and FDA regulatory frameworks, including CTA and IND processes.
  • Excellent scientific and business judgment.
  • Proven track record practicing sound judgment as it relates to risk assessment.
  • Understanding of GMP, GLP, and GCP.
  • Understanding of where to seek and how to interpret regulatory information.
  • Excellent verbal and written communication skills.
  • Professional attitude and strong interpersonal skills.
  • Ability to work well with a multi-disciplinary team.

Altasciences provides an integrated CRO that handles the full early‑phase drug development path, from preclinical testing through clinical proof of concept and into manufacturing. Its approach combines discovery support, safety testing, clinical trial execution, and in‑house manufacturing to run programs under one roof. This contrasts with competitors that require pharma and biotech clients to source services from multiple vendors, adding complexity and risk; Altasciences streamlines the process by coordinating all steps. The company aims to help innovator drug programs move quickly and efficiently, delivering integrated data to de‑risk decisions and speed progression to later stages.

Company Size

1,001-5,000

Company Stage

Early VC

Total Funding

$6.7M

Headquarters

Laval, Canada

Founded

1976

Simplify Jobs

Simplify's Take

What believers are saying

  • Biotech/pharma consolidation demand for single-vendor early-phase development solutions increases.
  • 3D tissue technology adoption reduces animal testing costs and accelerates regulatory approval timelines.
  • Geographic footprint and participant database enable rapid enrollment for mid-size biopharma sponsors.

What critics are saying

  • Novo Holdings divesting Altasciences signals poor financial performance and operational cutbacks.
  • Charles River aggressive pricing on integrated packages captures 20% mid-size biopharma contracts.
  • AI-driven preclinical platforms from Insilico Medicine displace traditional animal safety pharmacology testing.

What makes Altasciences unique

  • Integrated CRO/CDMO spanning preclinical safety testing through Phase IV bioanalysis and manufacturing.
  • 9 North American facilities with 500,000+ participant database conducting 285+ trials annually.
  • VoxCell partnership integrates 3D tissue technology for human-relevant preclinical testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance & Telehealth Programs

Remote Work Options

Company News

GlobeNewswire
Mar 16th, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...

Business Wire
Aug 20th, 2025
Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

EcoVadis, the world's most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company's commitment to a sustainable future and a reduced environmental footprint.

Yahoo Finance
Jul 31st, 2025
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment.

Postmedia Network
Mar 28th, 2025
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category

For 14 years, Outsourced Pharma's CDMO Leadership Awards have recognized the top-performing contract development and manufacturing organizations based on comprehensive industry research, and feedback from sponsors.

BioSpace
May 29th, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities

Altasciences receives 2024 CRO Leadership Award for Capabilities.

INACTIVE